Bill Text: IL HB2534 | 2017-2018 | 100th General Assembly | Engrossed
NOTE: There are more recent revisions of this legislation. Read Latest Draft
Bill Title: Amends the Illinois Controlled Substances Act. Requires that to be illegal a drug analog must not be approved by the United States Food and Drug Administration or, if approved, it is not dispensed or possessed in accordance with State and federal law. Defines "controlled substance" to include a synthetic drug enumerated as a scheduled drug under the Act. Adds chemical structural classes of synthetic cannabinoids and piperazines to the list of Schedule I controlled substances. Includes certain substances approved by the FDA which are not dispensed or possessed in accordance with State or federal law and certain modified substances.
Spectrum: Slight Partisan Bill (Republican 42-22)
Status: (Passed) 2017-08-25 - Public Act . . . . . . . . . 100-0368 [HB2534 Detail]
Download: Illinois-2017-HB2534-Engrossed.html
Bill Title: Amends the Illinois Controlled Substances Act. Requires that to be illegal a drug analog must not be approved by the United States Food and Drug Administration or, if approved, it is not dispensed or possessed in accordance with State and federal law. Defines "controlled substance" to include a synthetic drug enumerated as a scheduled drug under the Act. Adds chemical structural classes of synthetic cannabinoids and piperazines to the list of Schedule I controlled substances. Includes certain substances approved by the FDA which are not dispensed or possessed in accordance with State or federal law and certain modified substances.
Spectrum: Slight Partisan Bill (Republican 42-22)
Status: (Passed) 2017-08-25 - Public Act . . . . . . . . . 100-0368 [HB2534 Detail]
Download: Illinois-2017-HB2534-Engrossed.html
| |||||||
| |||||||
| |||||||
1 | AN ACT concerning criminal law.
| ||||||
2 | Be it enacted by the People of the State of Illinois,
| ||||||
3 | represented in the General Assembly:
| ||||||
4 | Section 5. The Illinois Controlled Substances Act is | ||||||
5 | amended by changing Sections 204, 206, 208, 401, and 402 as | ||||||
6 | follows:
| ||||||
7 | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | ||||||
8 | Sec. 204. (a) The controlled substances listed in this | ||||||
9 | Section are
included in Schedule I. | ||||||
10 | (b) Unless specifically excepted or unless listed in | ||||||
11 | another
schedule, any of the following opiates, including their | ||||||
12 | isomers,
esters, ethers, salts, and salts of isomers, esters, | ||||||
13 | and ethers,
whenever the existence of such isomers, esters, | ||||||
14 | ethers and salts is
possible within the specific chemical | ||||||
15 | designation: | ||||||
16 | (1) Acetylmethadol; | ||||||
17 | (1.1) Acetyl-alpha-methylfentanyl | ||||||
18 | (N-[1-(1-methyl-2-phenethyl)-
| ||||||
19 | 4-piperidinyl]-N-phenylacetamide); | ||||||
20 | (2) Allylprodine; | ||||||
21 | (3) Alphacetylmethadol, except
| ||||||
22 | levo-alphacetylmethadol (also known as levo-alpha-
| ||||||
23 | acetylmethadol, levomethadyl acetate, or LAAM); |
| |||||||
| |||||||
1 | (4) Alphameprodine; | ||||||
2 | (5) Alphamethadol; | ||||||
3 | (6) Alpha-methylfentanyl
| ||||||
4 | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| ||||||
5 | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| ||||||
6 | propanilido) piperidine; | ||||||
7 | (6.1) Alpha-methylthiofentanyl
| ||||||
8 | (N-[1-methyl-2-(2-thienyl)ethyl-
| ||||||
9 | 4-piperidinyl]-N-phenylpropanamide); | ||||||
10 | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | ||||||
11 | (7.1) PEPAP
| ||||||
12 | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | ||||||
13 | (8) Benzethidine; | ||||||
14 | (9) Betacetylmethadol; | ||||||
15 | (9.1) Beta-hydroxyfentanyl
| ||||||
16 | (N-[1-(2-hydroxy-2-phenethyl)-
| ||||||
17 | 4-piperidinyl]-N-phenylpropanamide); | ||||||
18 | (10) Betameprodine; | ||||||
19 | (11) Betamethadol; | ||||||
20 | (12) Betaprodine; | ||||||
21 | (13) Clonitazene; | ||||||
22 | (14) Dextromoramide; | ||||||
23 | (15) Diampromide; | ||||||
24 | (16) Diethylthiambutene; | ||||||
25 | (17) Difenoxin; | ||||||
26 | (18) Dimenoxadol; |
| |||||||
| |||||||
1 | (19) Dimepheptanol; | ||||||
2 | (20) Dimethylthiambutene; | ||||||
3 | (21) Dioxaphetylbutyrate; | ||||||
4 | (22) Dipipanone; | ||||||
5 | (23) Ethylmethylthiambutene; | ||||||
6 | (24) Etonitazene; | ||||||
7 | (25) Etoxeridine; | ||||||
8 | (26) Furethidine; | ||||||
9 | (27) Hydroxpethidine; | ||||||
10 | (28) Ketobemidone; | ||||||
11 | (29) Levomoramide; | ||||||
12 | (30) Levophenacylmorphan; | ||||||
13 | (31) 3-Methylfentanyl
| ||||||
14 | (N-[3-methyl-1-(2-phenylethyl)-
| ||||||
15 | 4-piperidyl]-N-phenylpropanamide); | ||||||
16 | (31.1) 3-Methylthiofentanyl
| ||||||
17 | (N-[(3-methyl-1-(2-thienyl)ethyl-
| ||||||
18 | 4-piperidinyl]-N-phenylpropanamide); | ||||||
19 | (32) Morpheridine; | ||||||
20 | (33) Noracymethadol; | ||||||
21 | (34) Norlevorphanol; | ||||||
22 | (35) Normethadone; | ||||||
23 | (36) Norpipanone; | ||||||
24 | (36.1) Para-fluorofentanyl
| ||||||
25 | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| ||||||
26 | 4-piperidinyl]propanamide); |
| |||||||
| |||||||
1 | (37) Phenadoxone; | ||||||
2 | (38) Phenampromide; | ||||||
3 | (39) Phenomorphan; | ||||||
4 | (40) Phenoperidine; | ||||||
5 | (41) Piritramide; | ||||||
6 | (42) Proheptazine; | ||||||
7 | (43) Properidine; | ||||||
8 | (44) Propiram; | ||||||
9 | (45) Racemoramide; | ||||||
10 | (45.1) Thiofentanyl
| ||||||
11 | (N-phenyl-N-[1-(2-thienyl)ethyl-
| ||||||
12 | 4-piperidinyl]-propanamide); | ||||||
13 | (46) Tilidine; | ||||||
14 | (47) Trimeperidine; | ||||||
15 | (48) Beta-hydroxy-3-methylfentanyl (other name:
| ||||||
16 | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| ||||||
17 | N-phenylpropanamide) ; . | ||||||
18 | (49) Furanyl fentanyl (FU-F); | ||||||
19 | (50) Butyryl fentanyl; | ||||||
20 | (51) Valeryl fentanyl; | ||||||
21 | (52) Acetyl fentanyl; | ||||||
22 | (53) Beta-hydroxy-thiofentanyl; | ||||||
23 | (54) 3,4-dichloro-N-[2-
| ||||||
24 | (dimethylamino)cyclohexyl]-N-
| ||||||
25 | methylbenzamide (U-47700); | ||||||
26 | (55) 4-chloro-N-[1-[2-
|
| |||||||
| |||||||
1 | (4-nitrophenyl)ethyl]-2-piperidinylidene]-
| ||||||
2 | benzenesulfonamide (W-18); | ||||||
3 | (56) 4-chloro-N-[1-(2-phenylethyl)
| ||||||
4 | -2-piperidinylidene]-benzenesulfonamide (W-15); | ||||||
5 | (57) acrylfentanyl (acryloylfentanyl). | ||||||
6 | (c) Unless specifically excepted or unless listed in | ||||||
7 | another
schedule, any of the following opium derivatives, its | ||||||
8 | salts, isomers
and salts of isomers, whenever the existence of | ||||||
9 | such salts, isomers and
salts of isomers is possible within the | ||||||
10 | specific chemical designation: | ||||||
11 | (1) Acetorphine; | ||||||
12 | (2) Acetyldihydrocodeine; | ||||||
13 | (3) Benzylmorphine; | ||||||
14 | (4) Codeine methylbromide; | ||||||
15 | (5) Codeine-N-Oxide; | ||||||
16 | (6) Cyprenorphine; | ||||||
17 | (7) Desomorphine; | ||||||
18 | (8) Diacetyldihydromorphine (Dihydroheroin); | ||||||
19 | (9) Dihydromorphine; | ||||||
20 | (10) Drotebanol; | ||||||
21 | (11) Etorphine (except hydrochloride salt); | ||||||
22 | (12) Heroin; | ||||||
23 | (13) Hydromorphinol; | ||||||
24 | (14) Methyldesorphine; | ||||||
25 | (15) Methyldihydromorphine; | ||||||
26 | (16) Morphine methylbromide; |
| |||||||
| |||||||
1 | (17) Morphine methylsulfonate; | ||||||
2 | (18) Morphine-N-Oxide; | ||||||
3 | (19) Myrophine; | ||||||
4 | (20) Nicocodeine; | ||||||
5 | (21) Nicomorphine; | ||||||
6 | (22) Normorphine; | ||||||
7 | (23) Pholcodine; | ||||||
8 | (24) Thebacon. | ||||||
9 | (d) Unless specifically excepted or unless listed in | ||||||
10 | another
schedule, any material, compound, mixture, or | ||||||
11 | preparation which contains
any quantity of the following | ||||||
12 | hallucinogenic substances, or which
contains any of its salts, | ||||||
13 | isomers and salts of isomers, whenever the
existence of such | ||||||
14 | salts, isomers, and salts of isomers is possible
within the | ||||||
15 | specific chemical designation (for the purposes of this
| ||||||
16 | paragraph only, the term "isomer" includes the optical, | ||||||
17 | position and
geometric isomers): | ||||||
18 | (1) 3,4-methylenedioxyamphetamine
| ||||||
19 | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| ||||||
20 | methylenedioxyamphetamine, MDA); | ||||||
21 | (1.1) Alpha-ethyltryptamine
| ||||||
22 | (some trade or other names: etryptamine;
| ||||||
23 | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| ||||||
24 | 3-(2-aminobutyl)indole; a-ET; and AET); | ||||||
25 | (2) 3,4-methylenedioxymethamphetamine (MDMA); | ||||||
26 | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
| |||||||
| |||||||
1 | (also known as: N-ethyl-alpha-methyl-
| ||||||
2 | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| ||||||
3 | and MDEA); | ||||||
4 | (2.2) N-Benzylpiperazine (BZP); | ||||||
5 | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | ||||||
6 | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | ||||||
7 | (4) 3,4,5-trimethoxyamphetamine (TMA); | ||||||
8 | (5) (Blank); | ||||||
9 | (6) Diethyltryptamine (DET); | ||||||
10 | (7) Dimethyltryptamine (DMT); | ||||||
11 | (7.1) 5-Methoxy-diallyltryptamine; | ||||||
12 | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | ||||||
13 | (9) Ibogaine (some trade and other names:
| ||||||
14 | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| ||||||
15 | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| ||||||
16 | indole; Tabernanthe iboga); | ||||||
17 | (10) Lysergic acid diethylamide; | ||||||
18 | (10.1) Salvinorin A; | ||||||
19 | (10.5) Salvia divinorum (meaning all parts of the plant | ||||||
20 | presently classified
botanically as Salvia divinorum, | ||||||
21 | whether growing or not, the
seeds thereof, any extract from | ||||||
22 | any part of that plant, and every compound,
manufacture, | ||||||
23 | salts, isomers, and salts of
isomers whenever the existence | ||||||
24 | of such salts, isomers, and salts of
isomers is possible | ||||||
25 | within the specific chemical designation, derivative, | ||||||
26 | mixture, or preparation of that plant, its
seeds or |
| |||||||
| |||||||
1 | extracts);
| ||||||
2 | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | ||||||
3 | (12) Peyote (meaning all parts of the plant presently | ||||||
4 | classified
botanically as Lophophora williamsii
Lemaire, | ||||||
5 | whether growing or not, the
seeds thereof, any extract from | ||||||
6 | any part of that plant, and every compound,
manufacture, | ||||||
7 | salts, derivative, mixture, or preparation of that plant, | ||||||
8 | its
seeds or extracts); | ||||||
9 | (13) N-ethyl-3-piperidyl benzilate (JB 318); | ||||||
10 | (14) N-methyl-3-piperidyl benzilate; | ||||||
11 | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| ||||||
12 | (also known as N-hydroxy-alpha-methyl-
| ||||||
13 | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | ||||||
14 | (15) Parahexyl; some trade or other names:
| ||||||
15 | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| ||||||
16 | dibenzo (b,d) pyran; Synhexyl; | ||||||
17 | (16) Psilocybin; | ||||||
18 | (17) Psilocyn; | ||||||
19 | (18) Alpha-methyltryptamine (AMT); | ||||||
20 | (19) 2,5-dimethoxyamphetamine
| ||||||
21 | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | ||||||
22 | (20) 4-bromo-2,5-dimethoxyamphetamine
| ||||||
23 | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| ||||||
24 | 4-bromo-2,5-DMA); | ||||||
25 | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| ||||||
26 | Some trade or other names: 2-(4-bromo-
|
| |||||||
| |||||||
1 | 2,5-dimethoxyphenyl)-1-aminoethane;
| ||||||
2 | alpha-desmethyl DOB, 2CB, Nexus; | ||||||
3 | (21) 4-methoxyamphetamine
| ||||||
4 | (4-methoxy-alpha-methylphenethylamine;
| ||||||
5 | paramethoxyamphetamine; PMA); | ||||||
6 | (22) (Blank); | ||||||
7 | (23) Ethylamine analog of phencyclidine.
| ||||||
8 | Some trade or other names:
| ||||||
9 | N-ethyl-1-phenylcyclohexylamine,
| ||||||
10 | (1-phenylcyclohexyl) ethylamine,
| ||||||
11 | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | ||||||
12 | (24) Pyrrolidine analog of phencyclidine. Some trade | ||||||
13 | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | ||||||
14 | PHP; | ||||||
15 | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | ||||||
16 | (26) 2,5-dimethoxy-4-ethylamphetamine
| ||||||
17 | (another name: DOET); | ||||||
18 | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| ||||||
19 | (another name: TCPy); | ||||||
20 | (28) (Blank); | ||||||
21 | (29) Thiophene analog of phencyclidine (some trade
| ||||||
22 | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| ||||||
23 | 2-thienyl analog of phencyclidine; TPCP; TCP); | ||||||
24 | (29.1) Benzothiophene analog of phencyclidine Some | ||||||
25 | trade or other names: BTCP or benocyclidine; | ||||||
26 | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); |
| |||||||
| |||||||
1 | (30) Bufotenine (some trade or other names:
| ||||||
2 | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| ||||||
3 | 3-(2-dimethylaminoethyl)-5-indolol;
| ||||||
4 | 5-hydroxy-N,N-dimethyltryptamine;
| ||||||
5 | N,N-dimethylserotonin; mappine); | ||||||
6 | (31) (Blank); 1-Pentyl-3-(1-naphthoyl)indole | ||||||
7 | Some trade or other names: JWH-018; | ||||||
8 | (32) (Blank); 1-Butyl-3-(1-naphthoyl)indole | ||||||
9 | Some trade or other names: JWH-073; | ||||||
10 | (33) (Blank); 1-[(5-fluoropentyl)-1H-indol-3-yl]- | ||||||
11 | (2-iodophenyl)methanone | ||||||
12 | Some trade or other names: AM-694; | ||||||
13 | (34) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | ||||||
14 | (2-methyloctan-2-yl)phenol | ||||||
15 | Some trade or other names: CP 47,497 | ||||||
16 | and its C6, C8 and C9 homologs; | ||||||
17 | (34.5) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | ||||||
18 | (2-methyloctan-2-yl)phenol), where side chain n=5; | ||||||
19 | and homologues where side chain n=4, 6, or 7; Some | ||||||
20 | trade or other names: CP 47,497; | ||||||
21 | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | ||||||
22 | (2-methyloctan-2-yl)-6a,7, | ||||||
23 | 10,10a-tetrahydrobenzo[c]chromen-1-ol | ||||||
24 | Some trade or other names: HU-210; | ||||||
25 | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | ||||||
26 | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- |
| |||||||
| |||||||
1 | tetrahydrobenzo[c]chromen-1-ol, its isomers, | ||||||
2 | salts, and salts of isomers; Some trade or other | ||||||
3 | names: HU-210, Dexanabinol; | ||||||
4 | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | ||||||
5 | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | ||||||
6 | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | ||||||
7 | Some trade or other names: HU-211; | ||||||
8 | (37) (Blank); (2-methyl-1-propyl-1H-indol- | ||||||
9 | 3-yl)-1-naphthalenyl-methanone | ||||||
10 | Some trade or other names: JWH-015; | ||||||
11 | (38) (Blank); 4-methoxynaphthalen-1-yl- | ||||||
12 | (1-pentylindol-3-yl)methanone | ||||||
13 | Some trade or other names: JWH-081; | ||||||
14 | (39) (Blank); 1-Pentyl-3-(4-methyl-1-naphthoyl)indole | ||||||
15 | Some trade or other names: JWH-122; | ||||||
16 | (40) (Blank); 2-(2-methylphenyl)-1-(1-pentyl- | ||||||
17 | 1H-indol-3-yl)-ethanone | ||||||
18 | Some trade or other names: JWH-251; | ||||||
19 | (41) (Blank); 1-(2-cyclohexylethyl)-3- | ||||||
20 | (2-methoxyphenylacetyl)indole | ||||||
21 | Some trade or other names: RCS-8, BTW-8 and SR-18; | ||||||
22 | (42) Any compound structurally derived from | ||||||
23 | 3-(1-naphthoyl)indole or 1H-indol-3-yl- | ||||||
24 | (1-naphthyl)methane by substitution at the | ||||||
25 | nitrogen atom of the indole ring by alkyl, haloalkyl, | ||||||
26 | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
| |||||||
| |||||||
1 | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, | ||||||
2 | or 2-(4-morpholinyl)ethyl whether or not further | ||||||
3 | substituted in the indole ring to any extent, whether | ||||||
4 | or not substituted in the naphthyl ring to any extent. | ||||||
5 | Examples of this structural class include, but are | ||||||
6 | not limited to, JWH-018, AM-2201, JWH-175, JWH-184, | ||||||
7 | and JWH-185; | ||||||
8 | (43) Any compound structurally derived from | ||||||
9 | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | ||||||
10 | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | ||||||
11 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl | ||||||
12 | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, | ||||||
13 | or 2-(4-morpholinyl)ethyl, whether or not further | ||||||
14 | substituted in the pyrrole ring to any extent, whether | ||||||
15 | or not substituted in the naphthyl ring to any extent. | ||||||
16 | Examples of this structural class include, but are not | ||||||
17 | limited to, JWH-030, JWH-145, JWH-146, JWH-307, and | ||||||
18 | JWH-368; | ||||||
19 | (44) Any compound structurally derived from | ||||||
20 | 1-(1-naphthylmethyl)indene by substitution | ||||||
21 | at the 3-position of the indene ring by alkyl, haloalkyl, | ||||||
22 | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | ||||||
23 | halide, alkyl aryl halide, 1-(N-methyl- | ||||||
24 | 2-piperidinyl)methyl, or 2-(4- | ||||||
25 | morpholinyl)ethyl whether or not further substituted in | ||||||
26 | the indene ring to any extent, whether or not substituted |
| |||||||
| |||||||
1 | in the naphthyl ring to any extent. Examples of | ||||||
2 | this structural class include, but are not | ||||||
3 | limited to, JWH-176; | ||||||
4 | (45) Any compound structurally derived from | ||||||
5 | 3-phenylacetylindole by substitution at the | ||||||
6 | nitrogen atom of the indole ring with alkyl, haloalkyl, | ||||||
7 | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | ||||||
8 | halide, alkyl aryl halide, 1-(N-methyl-2- | ||||||
9 | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | ||||||
10 | whether or not further substituted in the indole ring | ||||||
11 | to any extent, whether or not substituted in the phenyl | ||||||
12 | ring to any extent. Examples of this structural | ||||||
13 | class include, but are not limited to, JWH-167, | ||||||
14 | JWH-250, JWH-251, and RCS-8; | ||||||
15 | (46) Any compound structurally derived from | ||||||
16 | 2-(3-hydroxycyclohexyl)phenol by substitution | ||||||
17 | at the 5-position of the phenolic ring by alkyl, | ||||||
18 | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | ||||||
19 | aryl halide, alkyl aryl halide, 1-(N-methyl-2- | ||||||
20 | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | ||||||
21 | whether or not substituted in the cyclohexyl ring to any | ||||||
22 | extent. Examples of this structural class | ||||||
23 | include, but are not limited to, CP 47, | ||||||
24 | 497 and its C8 homologue (cannabicyclohexanol); | ||||||
25 | (46.1) Any compound structurally | ||||||
26 | derived from Benzoylindoles: Any compound |
| |||||||
| |||||||
1 | containing a 3-(benzoyl) indole structure with | ||||||
2 | substitution at the nitrogen atom of the | ||||||
3 | indole ring by an alkyl, haloalkyl, alkenyl, | ||||||
4 | cycloalkylmethyl, cycloalkylethyl, | ||||||
5 | aryl halide, alkyl aryl halide, | ||||||
6 | 1-(N-methyl-2-piperidinyl)methyl, | ||||||
7 | or 2-(4-morpholinyl)ethyl group | ||||||
8 | whether or not further substituted | ||||||
9 | in the indole ring to any extent and | ||||||
10 | whether or not substituted in the phenyl ring | ||||||
11 | to any extent. Examples of this structural class | ||||||
12 | include, but are not limited , to , AM-630, | ||||||
13 | AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; | ||||||
14 | (47) (Blank); 3,4-Methylenedioxymethcathinone | ||||||
15 | Some trade or other names: Methylone; | ||||||
16 | (48) (Blank); 3,4-Methyenedioxypyrovalerone | ||||||
17 | Some trade or other names: MDPV; | ||||||
18 | (49) (Blank); 4-Methylmethcathinone | ||||||
19 | Some trade or other names: Mephedrone; | ||||||
20 | (50) (Blank); 4-methoxymethcathinone; | ||||||
21 | (51) (Blank); 4-Fluoromethcathinone; | ||||||
22 | (52) (Blank); 3-Fluoromethcathinone; | ||||||
23 | (53) 2,5-Dimethoxy-4-(n)-propylthio- | ||||||
24 | phenethylamine ; | ||||||
25 | Some trade or other names: 2C-T-7; | ||||||
26 | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine |
| |||||||
| |||||||
1 | Some trade or other names: 2C-E; | ||||||
2 | (53.2) 2,5-dimethoxy-4-methylphenethylamine | ||||||
3 | Some trade or other names: 2C-D; | ||||||
4 | (53.3) 4-chloro-2,5-dimethoxyphenethylamine | ||||||
5 | Some trade or other names: 2C-C; | ||||||
6 | (53.4) 4-iodo-2,5-dimethoxyphenethylamine | ||||||
7 | Some trade or other names: 2C-I; | ||||||
8 | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine | ||||||
9 | Some trade or other names: 2C-T-2; | ||||||
10 | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine | ||||||
11 | Some trade or other names: 2C-T-4; | ||||||
12 | (53.7) 2,5-dimethoxyphenethylamine | ||||||
13 | Some trade or other names: 2C-H; | ||||||
14 | (53.8) 2,5-dimethoxy-4-nitrophenethylamine | ||||||
15 | Some trade or other names: 2C-N; | ||||||
16 | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine | ||||||
17 | Some trade or other names: 2C-P; | ||||||
18 | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine | ||||||
19 | Some trade or other names: 2C-G; | ||||||
20 | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | ||||||
21 | phenethylamine referred to in subparagraphs (20.1), (53), | ||||||
22 | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | ||||||
23 | (53.8), (53.9), and (53.10) including, but not limited to, | ||||||
24 | 25I-NBOMe and 25C-NBOMe; | ||||||
25 | (54) 5-Methoxy-N,N-diisopropyltryptamine; | ||||||
26 | (55) (Blank); Pentedrone; |
| |||||||
| |||||||
1 | (56) (Blank); 4-iodo-2,5-dimethoxy-N-((2-methoxy | ||||||
2 | phenyl)methyl)-benzeneethanamine | ||||||
3 | (trade or other name: 25I-NBOMe); | ||||||
4 | (57) (Blank); 4-chloro-2,5-dimethoxy- | ||||||
5 | N-[(2-methoxyphenyl) methyl]-benzeneethanamine | ||||||
6 | (trade or other name: 25C-NBOMe); | ||||||
7 | (58) (Blank); 4-bromo-2,5-dimethoxy | ||||||
8 | -N-[(2-methoxyphenyl) methyl]-benzeneethanamine | ||||||
9 | (trade or other name: 25B-NBOMe); | ||||||
10 | (59) 3-cyclopropoylindole with | ||||||
11 | substitution at the nitrogen atom of the | ||||||
12 | indole ring by alkyl, haloalkyl, alkenyl, | ||||||
13 | cycloalkylmethyl, cycloalkylethyl, aryl | ||||||
14 | halide, alkyl aryl halide, | ||||||
15 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
16 | 2-(4-morpholinyl)ethyl, whether or not | ||||||
17 | further substituted on the indole ring | ||||||
18 | to any extent, whether or not substituted | ||||||
19 | on the cyclopropyl ring to any extent: | ||||||
20 | including , but not limited to , XLR11, | ||||||
21 | UR144, FUB-144; | ||||||
22 | (60) 3-adamantoylindole with | ||||||
23 | substitution at the nitrogen atom of the | ||||||
24 | indole ring by alkyl, haloalkyl, alkenyl, | ||||||
25 | cycloalkylmethyl, cycloalkylethyl, | ||||||
26 | aryl halide, alkyl aryl halide, |
| |||||||
| |||||||
1 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
2 | 2-(4-morpholinyl)ethyl, whether or not | ||||||
3 | further substituted on the indole ring to | ||||||
4 | any extent, whether or not substituted on | ||||||
5 | the adamantyl ring to any extent: including , | ||||||
6 | but not limited to , AB-001; | ||||||
7 | (61) N-(adamantyl)-indole-3-carboxamide | ||||||
8 | with substitution at the nitrogen atom of the | ||||||
9 | indole ring by alkyl, haloalkyl, alkenyl, | ||||||
10 | cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||||||
11 | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, | ||||||
12 | or 2-(4-morpholinyl)ethyl, whether or not further | ||||||
13 | substituted on the indole ring to any extent, whether | ||||||
14 | or not substituted on the adamantyl ring to any | ||||||
15 | extent: including , but not limited to , | ||||||
16 | APICA/2NE-1, STS-135; | ||||||
17 | (62) N-(adamantyl)-indazole-3-carboxamide | ||||||
18 | with substitution at a nitrogen atom of the indazole | ||||||
19 | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | ||||||
20 | cycloalkylethyl, aryl halide, alkyl aryl halide, | ||||||
21 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
22 | 2-(4-morpholinyl)ethyl, whether or not further | ||||||
23 | substituted on the indazole ring to any extent, | ||||||
24 | whether or not substituted on the adamantyl | ||||||
25 | ring to any extent: including , but not limited | ||||||
26 | to , AKB48, 5F-AKB48; |
| |||||||
| |||||||
1 | (63) 1H-indole-3-carboxylic acid 8-quinolinyl | ||||||
2 | ester with substitution at the nitrogen atom of the | ||||||
3 | indole ring by alkyl, haloalkyl, alkenyl, | ||||||
4 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl | ||||||
5 | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
6 | 2-(4-morpholinyl)ethyl, whether or not further | ||||||
7 | substituted on the indole ring to any extent, | ||||||
8 | whether or not substituted on the quinoline ring | ||||||
9 | to any extent: including , but not limited to , PB22, | ||||||
10 | 5F-PB22, FUB-PB-22; | ||||||
11 | (64) 3-(1-naphthoyl)indazole with | ||||||
12 | substitution at the nitrogen atom of the | ||||||
13 | indazole ring by alkyl, haloalkyl, | ||||||
14 | alkenyl, cycloalkylmethyl, cycloalkylethyl, | ||||||
15 | aryl halide, alkyl aryl halide, | ||||||
16 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
17 | 2-(4-morpholinyl)ethyl, whether or not further | ||||||
18 | substituted on the indazole ring to any extent, | ||||||
19 | whether or not substituted on the naphthyl ring | ||||||
20 | to any extent: including , but not limited to , | ||||||
21 | THJ-018, THJ-2201; | ||||||
22 | (65) 2-(1-naphthoyl)benzimidazole with | ||||||
23 | substitution at the nitrogen atom of the benzimidazole | ||||||
24 | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | ||||||
25 | cycloalkylethyl, aryl halide, alkyl aryl halide, | ||||||
26 | 1-(N-methyl-2-piperidinyl)methyl, or |
| |||||||
| |||||||
1 | 2-(4-morpholinyl)ethyl, whether or not further | ||||||
2 | substituted on the benzimidazole ring to any extent, | ||||||
3 | whether or not substituted on the naphthyl ring to | ||||||
4 | any extent: including, but not limited to , FUBIMINA; | ||||||
5 | (66) N-(1-amino-3-methyl-1-oxobutan-2-yl) | ||||||
6 | -1H-indazole-3-carboxamide with substitution on the | ||||||
7 | nitrogen atom of the indazole ring by alkyl, | ||||||
8 | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | ||||||
9 | aryl halide, alkyl aryl halide, 1-(N-methyl-2- | ||||||
10 | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | ||||||
11 | whether or not further substituted on the indazole | ||||||
12 | ring to any extent: including , but not limited to , | ||||||
13 | AB-PINACA, AB-FUBINACA, AB-CHMINACA; | ||||||
14 | (67) N-(1-amino-3,3-dimethyl-1-oxobutan- | ||||||
15 | 2-yl)-1H-indazole-3-carboxamide with substitution | ||||||
16 | on the nitrogen atom of the indazole ring by alkyl, | ||||||
17 | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | ||||||
18 | aryl halide, alkyl aryl halide, 1-(N-methyl-2- | ||||||
19 | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether | ||||||
20 | or not further substituted on the indazole ring to any | ||||||
21 | extent: including , but not limited to , ADB-PINACA, | ||||||
22 | ADB-FUBINACA; | ||||||
23 | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- | ||||||
24 | 1H-indole-3-carboxamide with substitution on the nitrogen | ||||||
25 | atom of the indole ring by alkyl, haloalkyl, alkenyl, | ||||||
26 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl |
| |||||||
| |||||||
1 | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
2 | 2-(4-morpholinyl)ethyl, whether or not further | ||||||
3 | substituted on the indole ring to any extent: | ||||||
4 | including , but not limited to , ADBICA, 5F-ADBICA; | ||||||
5 | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)- | ||||||
6 | 1H-indole-3-carboxamide with substitution on the | ||||||
7 | nitrogen atom of the indole ring by alkyl, haloalkyl, | ||||||
8 | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | ||||||
9 | halide, alkyl aryl halide, 1-(N-methyl-2- | ||||||
10 | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | ||||||
11 | whether or not further substituted on the indole | ||||||
12 | ring to any extent: including , but not limited | ||||||
13 | to , ABICA, 5F-ABICA; | ||||||
14 | (70) Methyl 2-(1H-indazole-3-carboxamido)- | ||||||
15 | 3-methylbutanoate with substitution on the nitrogen | ||||||
16 | atom of the indazole ring by alkyl, haloalkyl, | ||||||
17 | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | ||||||
18 | halide, alkyl aryl halide, 1-(N-methyl-2- | ||||||
19 | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | ||||||
20 | whether or not further substituted on the indazole | ||||||
21 | ring to any extent: including , but not limited to , AMB, | ||||||
22 | 5F-AMB. | ||||||
23 | (71) Methyl 2-(1H-indazole-3-carboxamido)
| ||||||
24 | -3,3-dimethylbutanoate with substitution on the nitrogen
| ||||||
25 | atom of the indazole ring by alkyl, haloalkyl, alkenyl,
| ||||||
26 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
|
| |||||||
| |||||||
1 | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-
| ||||||
2 | (4-morpholinyl)ethyl, whether or not further substituted
| ||||||
3 | on the indazole ring to any extent: including, but not
| ||||||
4 | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | ||||||
5 | (72) Methyl 2-(1H-indole-3-carboxamido)-
| ||||||
6 | 3-methylbutanoate with substitution on the nitrogen atom
| ||||||
7 | of the indole ring by alkyl, haloalkyl, alkenyl,
| ||||||
8 | cycloalkylmethyl, cycloalkylethyl, aryl halide,
| ||||||
9 | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
| ||||||
10 | or 2-(4-morpholinyl)ethyl, whether or not further
| ||||||
11 | substituted on the indazole ring to any extent:
| ||||||
12 | including, but not limited to, MMB018, MMB2201,
| ||||||
13 | and AMB-CHMICA; | ||||||
14 | (73) Methyl 2-(1H-indole-3-
| ||||||
15 | carboxamido)-3,3-dimethylbutanoate with substitution
| ||||||
16 | on the nitrogen atom of the indole ring by alkyl,
| ||||||
17 | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
| ||||||
18 | aryl halide, alkyl aryl halide, 1-(N-methyl-2-
| ||||||
19 | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
| ||||||
20 | whether or not further substituted on the
| ||||||
21 | indazole ring to any extent: including, but
| ||||||
22 | not limited to, MDMB-CHMICA; | ||||||
23 | (74) N-(1-Amino-1-oxo-3-phenylpropan
| ||||||
24 | -2-yl) -1H-indazole-3-carboxamide with
| ||||||
25 | substitution on the nitrogen atom of the indazole
| ||||||
26 | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
|
| |||||||
| |||||||
1 | cycloalkylethyl, aryl halide, alkyl aryl halide,
| ||||||
2 | 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-
| ||||||
3 | morpholinyl)ethyl, whether or not further
| ||||||
4 | substituted on the indazole ring to any
| ||||||
5 | extent: including, but not limited to, APP-CHMINACA,
| ||||||
6 | 5-fluoro-APP-PINACA; | ||||||
7 | (75) N-(1-Amino-1-oxo-3-phenylpropan
| ||||||
8 | -2-yl)-1H-indole-3-carboxamide with substitution on
| ||||||
9 | the nitrogen atom of the indole ring by alkyl,
| ||||||
10 | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
| ||||||
11 | aryl halide, alkyl aryl halide, 1-(N-methyl-2-
| ||||||
12 | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
| ||||||
13 | whether or not further substituted on the indazole
| ||||||
14 | ring to any extent: including, but not limited to,
| ||||||
15 | APP-PICA and 5-fluoro-APP-PICA; | ||||||
16 | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | ||||||
17 | 4-AcO-DMT; | ||||||
18 | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: Trade | ||||||
19 | name 5-MeO-MIPT; | ||||||
20 | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | ||||||
21 | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | ||||||
22 | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | ||||||
23 | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
| ||||||
24 | (4-HO-MiPT); | ||||||
25 | (82) Fluorophenylpiperazine; | ||||||
26 | (83) Methoxetamine; |
| |||||||
| |||||||
1 | (84) 1-(Ethylamino)-2-phenylpropan-2-
| ||||||
2 | one (iso-ethcathinone). | ||||||
3 | (e) Unless specifically excepted or unless listed in | ||||||
4 | another
schedule, any material, compound, mixture, or | ||||||
5 | preparation which contains
any quantity of the following | ||||||
6 | substances having a depressant effect on
the central nervous | ||||||
7 | system, including its salts, isomers, and salts of
isomers | ||||||
8 | whenever the existence of such salts, isomers, and salts of
| ||||||
9 | isomers is possible within the specific chemical designation: | ||||||
10 | (1) mecloqualone; | ||||||
11 | (2) methaqualone; and | ||||||
12 | (3) gamma hydroxybutyric acid. | ||||||
13 | (f) Unless specifically excepted or unless listed in | ||||||
14 | another schedule,
any material, compound, mixture, or | ||||||
15 | preparation which contains any quantity
of the following | ||||||
16 | substances having a stimulant effect on the central nervous
| ||||||
17 | system, including its salts, isomers, and salts of isomers: | ||||||
18 | (1) Fenethylline; | ||||||
19 | (2) N-ethylamphetamine; | ||||||
20 | (3) Aminorex (some other names:
| ||||||
21 | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| ||||||
22 | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| ||||||
23 | salts, optical isomers, and salts of optical isomers; | ||||||
24 | (4) Methcathinone (some other names:
| ||||||
25 | 2-methylamino-1-phenylpropan-1-one;
| ||||||
26 | Ephedrone; 2-(methylamino)-propiophenone;
|
| |||||||
| |||||||
1 | alpha-(methylamino)propiophenone; N-methylcathinone;
| ||||||
2 | methycathinone; Monomethylpropion; UR 1431) and its
| ||||||
3 | salts, optical isomers, and salts of optical isomers; | ||||||
4 | (5) Cathinone (some trade or other names:
| ||||||
5 | 2-aminopropiophenone; alpha-aminopropiophenone;
| ||||||
6 | 2-amino-1-phenyl-propanone; norephedrone); | ||||||
7 | (6) N,N-dimethylamphetamine (also known as:
| ||||||
8 | N,N-alpha-trimethyl-benzeneethanamine;
| ||||||
9 | N,N-alpha-trimethylphenethylamine); | ||||||
10 | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| ||||||
11 | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | ||||||
12 | (8) 3,4-Methylenedioxypyrovalerone (MDPV) ; . | ||||||
13 | (9) Halogenated amphetamines and
| ||||||
14 | methamphetamines – any compound derived from either
| ||||||
15 | amphetamine or methamphetamine through the substitution
| ||||||
16 | of a halogen on the phenyl ring, including, but not
| ||||||
17 | limited to, 2-fluoroamphetamine, 3-
| ||||||
18 | fluoroamphetamine and 4-fluoroamphetamine; | ||||||
19 | (10) Aminopropylbenzofuran (APB):
| ||||||
20 | including 4-(2-Aminopropyl) benzofuran, 5-
| ||||||
21 | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| ||||||
22 | benzofuran, and 7-(2-Aminopropyl) benzofuran; | ||||||
23 | (11) Aminopropyldihydrobenzofuran (APDB):
| ||||||
24 | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| ||||||
25 | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| ||||||
26 | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
|
| |||||||
| |||||||
1 | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | ||||||
2 | (12) Methylaminopropylbenzofuran
| ||||||
3 | (MAPB): including 4-(2-methylaminopropyl)
| ||||||
4 | benzofuran, 5-(2-methylaminopropyl)benzofuran,
| ||||||
5 | 6-(2-methylaminopropyl)benzofuran
| ||||||
6 | and 7-(2-methylaminopropyl)benzofuran. | ||||||
7 | (g) Temporary listing of substances subject to emergency | ||||||
8 | scheduling.
Any material, compound, mixture, or preparation | ||||||
9 | that contains any quantity
of the following substances: | ||||||
10 | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| ||||||
11 | (benzylfentanyl), its optical isomers, isomers, salts,
| ||||||
12 | and salts of isomers; | ||||||
13 | (2) N-[1(2-thienyl)
| ||||||
14 | methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
| ||||||
15 | its optical isomers, salts, and salts of isomers. | ||||||
16 | (h) Synthetic cathinones. Unless specifically excepted, | ||||||
17 | any chemical compound which is not approved by the United | ||||||
18 | States Food and Drug Administration or, if approved, is not | ||||||
19 | dispensed or possessed in accordance with State or federal law, | ||||||
20 | not including bupropion, structurally derived from | ||||||
21 | 2-aminopropan-1-one by substitution at the 1-position with | ||||||
22 | either phenyl, naphthyl, or thiophene ring systems, whether or | ||||||
23 | not the compound is further modified in one or more of the | ||||||
24 | following ways: | ||||||
25 | (1) by substitution in the ring system to | ||||||
26 | any extent with alkyl, alkylenedioxy, alkoxy, |
| |||||||
| |||||||
1 | haloalkyl, hydroxyl, or halide substituents, whether | ||||||
2 | or not further substituted in the ring system | ||||||
3 | by one or more other univalent substituents. | ||||||
4 | Examples of this class include, but are not | ||||||
5 | limited to, 3,4-Methylenedioxycathinone | ||||||
6 | (bk-MDA); | ||||||
7 | (2) by substitution at the 3-position | ||||||
8 | with an acyclic alkyl substituent. Examples of | ||||||
9 | this class include, but are not limited to, | ||||||
10 | 2-methylamino-1-phenylbutan-1-one | ||||||
11 | (buphedrone); or | ||||||
12 | (3) by substitution at the 2-amino nitrogen | ||||||
13 | atom with alkyl, dialkyl, benzyl, or methoxybenzyl | ||||||
14 | groups, or by inclusion of the 2-amino nitrogen atom | ||||||
15 | in a cyclic structure. Examples of this class include, | ||||||
16 | but are not limited to, Dimethylcathinone, Ethcathinone, | ||||||
17 | and a-Pyrrolidinopropiophenone (a-PPP). | ||||||
18 | (Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised | ||||||
19 | 10-25-16.)
| ||||||
20 | (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
| ||||||
21 | Sec. 206. (a) The controlled substances listed in this | ||||||
22 | Section are
included in Schedule II.
| ||||||
23 | (b) Unless specifically excepted or unless listed in | ||||||
24 | another
schedule, any of the following substances whether | ||||||
25 | produced directly or
indirectly by extraction from substances |
| |||||||
| |||||||
1 | of vegetable origin, or
independently by means of chemical | ||||||
2 | synthesis, or by combination of
extraction and chemical | ||||||
3 | synthesis:
| ||||||
4 | (1) Opium and opiates, and any salt, compound, | ||||||
5 | derivative or
preparation of opium or opiate, excluding | ||||||
6 | apomorphine, dextrorphan,
levopropoxyphene,
nalbuphine, | ||||||
7 | nalmefene, naloxone, and naltrexone, and their respective
| ||||||
8 | salts, but including the following:
| ||||||
9 | (i) Raw Opium;
| ||||||
10 | (ii) Opium extracts;
| ||||||
11 | (iii) Opium fluid extracts;
| ||||||
12 | (iv) Powdered opium;
| ||||||
13 | (v) Granulated opium;
| ||||||
14 | (vi) Tincture of opium;
| ||||||
15 | (vii) Codeine;
| ||||||
16 | (viii) Ethylmorphine;
| ||||||
17 | (ix) Etorphine Hydrochloride;
| ||||||
18 | (x) Hydrocodone;
| ||||||
19 | (xi) Hydromorphone;
| ||||||
20 | (xii) Metopon;
| ||||||
21 | (xiii) Morphine;
| ||||||
22 | (xiii.5) 6-Monoacetylmorphine;
| ||||||
23 | (xiv) Oxycodone;
| ||||||
24 | (xv) Oxymorphone;
| ||||||
25 | (xv.5) Tapentadol;
| ||||||
26 | (xvi) Thebaine;
|
| |||||||
| |||||||
1 | (xvii) Thebaine-derived butorphanol.
| ||||||
2 | (xviii) Methorphan Dextromethorphan , except drug | ||||||
3 | products containing dextromethorphan that may be | ||||||
4 | dispensed pursuant to a prescription order of a | ||||||
5 | practitioner and are sold in compliance with the safety | ||||||
6 | and labeling standards as set forth by the United | ||||||
7 | States Food and Drug Administration, or drug products | ||||||
8 | containing dextromethorphan that are sold in solid, | ||||||
9 | tablet, liquid, capsule, powder, thin film, or gel form | ||||||
10 | and which are formulated, packaged, and sold in dosages | ||||||
11 | and concentrations for use as an over-the-counter drug | ||||||
12 | product. For the purposes of this Section, | ||||||
13 | "over-the-counter drug product" means a drug that is | ||||||
14 | available to consumers without a prescription and sold | ||||||
15 | in compliance with the safety and labeling standards as | ||||||
16 | set forth by the United States Food and Drug | ||||||
17 | Administration.
| ||||||
18 | (2) Any salt, compound, isomer, derivative or | ||||||
19 | preparation thereof
which is chemically equivalent or | ||||||
20 | identical with any of the substances
referred to in | ||||||
21 | subparagraph (1), but not including the isoquinoline
| ||||||
22 | alkaloids of opium;
| ||||||
23 | (3) Opium poppy and poppy straw;
| ||||||
24 | (4) Coca leaves and any salt, compound, isomer, salt of | ||||||
25 | an isomer,
derivative, or preparation of coca leaves | ||||||
26 | including cocaine or ecgonine,
and any salt, compound, |
| |||||||
| |||||||
1 | isomer, derivative, or preparation thereof which is
| ||||||
2 | chemically equivalent or identical with any of these | ||||||
3 | substances, but not
including decocainized coca leaves or | ||||||
4 | extractions of coca leaves which do
not contain cocaine or | ||||||
5 | ecgonine (for the purpose of this paragraph, the
term | ||||||
6 | "isomer" includes optical, positional and geometric | ||||||
7 | isomers);
| ||||||
8 | (5) Concentrate of poppy straw (the crude extract of | ||||||
9 | poppy straw in
either liquid, solid or powder form which | ||||||
10 | contains the phenanthrine
alkaloids of the opium poppy).
| ||||||
11 | (c) Unless specifically excepted or unless listed in | ||||||
12 | another
schedule any of the following opiates, including their | ||||||
13 | isomers, esters,
ethers, salts, and salts of isomers, whenever | ||||||
14 | the existence of these
isomers, esters, ethers and salts is | ||||||
15 | possible within the specific
chemical designation, dextrorphan | ||||||
16 | excepted:
| ||||||
17 | (1) Alfentanil;
| ||||||
18 | (1.1) Carfentanil;
| ||||||
19 | (1.2) Thiafentanyl;
| ||||||
20 | (2) Alphaprodine;
| ||||||
21 | (3) Anileridine;
| ||||||
22 | (4) Bezitramide;
| ||||||
23 | (5) Bulk Dextropropoxyphene (non-dosage forms);
| ||||||
24 | (6) Dihydrocodeine;
| ||||||
25 | (7) Diphenoxylate;
| ||||||
26 | (8) Fentanyl;
|
| |||||||
| |||||||
1 | (9) Sufentanil;
| ||||||
2 | (9.5) Remifentanil;
| ||||||
3 | (10) Isomethadone;
| ||||||
4 | (11) (Blank); Levomethorphan;
| ||||||
5 | (12) Levorphanol (Levorphan);
| ||||||
6 | (13) Metazocine;
| ||||||
7 | (14) Methadone;
| ||||||
8 | (15) Methadone-Intermediate,
| ||||||
9 | 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
| ||||||
10 | (16) Moramide-Intermediate,
| ||||||
11 | 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
| ||||||
12 | acid;
| ||||||
13 | (17) Pethidine (meperidine);
| ||||||
14 | (18) Pethidine-Intermediate-A,
| ||||||
15 | 4-cyano-1-methyl-4-phenylpiperidine;
| ||||||
16 | (19) Pethidine-Intermediate-B,
| ||||||
17 | ethyl-4-phenylpiperidine-4-carboxylate;
| ||||||
18 | (20) Pethidine-Intermediate-C,
| ||||||
19 | 1-methyl-4-phenylpiperidine-4-carboxylic acid;
| ||||||
20 | (21) Phenazocine;
| ||||||
21 | (22) Piminodine;
| ||||||
22 | (23) Racemethorphan;
| ||||||
23 | (24) (Blank); Racemorphan;
| ||||||
24 | (25) Levo-alphacetylmethadol (some other names:
| ||||||
25 | levo-alpha-acetylmethadol,
levomethadyl acetate, LAAM).
| ||||||
26 | (d) Unless specifically excepted or unless listed in |
| |||||||
| |||||||
1 | another
schedule, any material, compound, mixture, or | ||||||
2 | preparation which contains
any quantity of the following | ||||||
3 | substances having a stimulant effect on
the central nervous | ||||||
4 | system:
| ||||||
5 | (1) Amphetamine, its salts, optical isomers, and salts | ||||||
6 | of its
optical isomers;
| ||||||
7 | (2) Methamphetamine, its salts, isomers, and salts of | ||||||
8 | its isomers;
| ||||||
9 | (3) Phenmetrazine and its salts;
| ||||||
10 | (4) Methylphenidate;
| ||||||
11 | (5) Lisdexamfetamine. | ||||||
12 | (e) Unless specifically excepted or unless listed in | ||||||
13 | another
schedule, any material, compound, mixture, or | ||||||
14 | preparation which contains
any quantity of the following | ||||||
15 | substances having a depressant effect on
the central nervous | ||||||
16 | system, including its salts, isomers, and salts of
isomers | ||||||
17 | whenever the existence of such salts, isomers, and salts of
| ||||||
18 | isomers is possible within the specific chemical designation:
| ||||||
19 | (1) Amobarbital;
| ||||||
20 | (2) Secobarbital;
| ||||||
21 | (3) Pentobarbital;
| ||||||
22 | (4) Pentazocine;
| ||||||
23 | (5) Phencyclidine;
| ||||||
24 | (6) Gluthethimide;
| ||||||
25 | (7) (Blank).
| ||||||
26 | (f) Unless specifically excepted or unless listed in |
| |||||||
| |||||||
1 | another schedule,
any material, compound, mixture, or | ||||||
2 | preparation which contains any quantity
of the following | ||||||
3 | substances:
| ||||||
4 | (1) Immediate precursor to amphetamine and | ||||||
5 | methamphetamine:
| ||||||
6 | (i) Phenylacetone
| ||||||
7 | Some trade or other names: phenyl-2-propanone;
| ||||||
8 | P2P; benzyl methyl ketone; methyl benzyl ketone.
| ||||||
9 | (2) Immediate precursors to phencyclidine:
| ||||||
10 | (i) 1-phenylcyclohexylamine;
| ||||||
11 | (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
| ||||||
12 | (3) Nabilone.
| ||||||
13 | (Source: P.A. 97-334, eff. 1-1-12.)
| ||||||
14 | (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
| ||||||
15 | Sec. 208.
(a) The controlled substances listed in this | ||||||
16 | Section are
included in Schedule III.
| ||||||
17 | (b) Unless specifically excepted or unless listed in | ||||||
18 | another
schedule, any material, compound, mixture, or | ||||||
19 | preparation which contains
any quantity of the following | ||||||
20 | substances having a stimulant effect on
the central nervous | ||||||
21 | system, including its salts, isomers (whether
optical | ||||||
22 | position, or geometric), and salts of such isomers whenever the
| ||||||
23 | existence of such salts, isomers, and salts of isomers is | ||||||
24 | possible
within the specific chemical designation;
| ||||||
25 | (1) Those compounds, mixtures, or preparations in |
| |||||||
| |||||||
1 | dosage unit form
containing any stimulant substances | ||||||
2 | listed in Schedule II which
compounds, mixtures, or | ||||||
3 | preparations were listed on August 25, 1971, as
excepted | ||||||
4 | compounds under Title 21, Code of Federal Regulations, | ||||||
5 | Section
308.32, and any other drug of the quantitative | ||||||
6 | composition shown in that
list for those drugs or which is | ||||||
7 | the same except that it contains a
lesser quantity of | ||||||
8 | controlled substances;
| ||||||
9 | (2) Benzphetamine;
| ||||||
10 | (3) Chlorphentermine;
| ||||||
11 | (4) Clortermine;
| ||||||
12 | (5) Phendimetrazine.
| ||||||
13 | (c) Unless specifically excepted or unless listed in | ||||||
14 | another
schedule, any material, compound, mixture, or | ||||||
15 | preparation which contains
any quantity of the following | ||||||
16 | substances having a potential for abuse
associated with a | ||||||
17 | depressant effect on the central nervous system:
| ||||||
18 | (1) Any compound, mixture, or preparation containing | ||||||
19 | amobarbital,
secobarbital, pentobarbital or any salt | ||||||
20 | thereof and one or more other
active medicinal ingredients | ||||||
21 | which are not listed in any schedule;
| ||||||
22 | (2) Any suppository dosage form containing | ||||||
23 | amobarbital,
secobarbital, pentobarbital or any salt of | ||||||
24 | any of these drugs and
approved by the Federal Food and | ||||||
25 | Drug Administration for marketing only
as a suppository;
| ||||||
26 | (3) Any substance which contains any quantity of a |
| |||||||
| |||||||
1 | derivative of
barbituric acid, or any salt thereof:
| ||||||
2 | (3.1) Aprobarbital; | ||||||
3 | (3.2) Butabarbital (secbutabarbital); | ||||||
4 | (3.3) Butalbital; | ||||||
5 | (3.4) Butobarbital (butethal);
| ||||||
6 | (4) Chlorhexadol;
| ||||||
7 | (5) Methyprylon;
| ||||||
8 | (6) Sulfondiethylmethane;
| ||||||
9 | (7) Sulfonethylmethane;
| ||||||
10 | (8) Sulfonmethane;
| ||||||
11 | (9) Lysergic acid;
| ||||||
12 | (10) Lysergic acid amide;
| ||||||
13 | (10.1) Tiletamine or zolazepam or both, or any salt of | ||||||
14 | either of them.
| ||||||
15 | Some trade or other names for a tiletamine-zolazepam
| ||||||
16 | combination product: Telazol.
| ||||||
17 | Some trade or other names for Tiletamine:
| ||||||
18 | 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
| ||||||
19 | Some trade or other names for zolazepam:
| ||||||
20 | 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
| ||||||
21 | [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
| ||||||
22 | (11) Any material, compound, mixture or preparation | ||||||
23 | containing not more
than 12.5 milligrams of pentazocine or | ||||||
24 | any of its salts, per 325 milligrams of
aspirin;
| ||||||
25 | (12) Any material, compound, mixture or preparation | ||||||
26 | containing not
more than 12.5 milligrams of pentazocine or |
| |||||||
| |||||||
1 | any of its salts, per 325
milligrams of acetaminophen;
| ||||||
2 | (13) Any material, compound, mixture or preparation | ||||||
3 | containing not more
than 50 milligrams of pentazocine or | ||||||
4 | any of its salts plus naloxone HCl USP
0.5 milligrams, per | ||||||
5 | dosage unit;
| ||||||
6 | (14) Ketamine;
| ||||||
7 | (15) Thiopental. | ||||||
8 | (d) Nalorphine.
| ||||||
9 | (d.5) Buprenorphine. | ||||||
10 | (e) Unless specifically excepted or unless listed in | ||||||
11 | another
schedule, any material, compound, mixture, or | ||||||
12 | preparation containing
limited quantities of any of the | ||||||
13 | following narcotic drugs, or their salts
calculated as the free | ||||||
14 | anhydrous base or alkaloid, as set forth below:
| ||||||
15 | (1) not more than 1.8 grams of codeine per 100
| ||||||
16 | milliliters or not more than 90 milligrams per dosage unit, | ||||||
17 | with an
equal or greater quantity of an isoquinoline | ||||||
18 | alkaloid of opium;
| ||||||
19 | (2) not more than 1.8 grams of codeine per 100
| ||||||
20 | milliliters or not more than 90 milligrams per dosage unit, | ||||||
21 | with one or
more active non-narcotic ingredients in | ||||||
22 | recognized therapeutic amounts;
| ||||||
23 | (3) (blank); not more than 300 milligrams of | ||||||
24 | dihydrocodeinone per 100 milliliters
or not more than 15 | ||||||
25 | milligrams per dosage
unit, with a fourfold or greater | ||||||
26 | quantity of an isoquinoline alkaloid of
opium;
|
| |||||||
| |||||||
1 | (4) (blank); not more than 300 milligrams of | ||||||
2 | dihydrocodeinone per 100 milliliters
or not more than 15 | ||||||
3 | milligrams per dosage
unit, with one or more active, | ||||||
4 | non-narcotic ingredients in recognized
therapeutic | ||||||
5 | amounts;
| ||||||
6 | (5) not more than 1.8 grams of dihydrocodeine
per 100 | ||||||
7 | milliliters or not more than 90 milligrams per dosage unit, | ||||||
8 | with
one or more active, non-narcotic ingredients in | ||||||
9 | recognized therapeutic
amounts;
| ||||||
10 | (6) not more than 300 milligrams of ethylmorphine per | ||||||
11 | 100 milliliters
or not more than 15 milligrams per dosage
| ||||||
12 | unit, with one or more active, non-narcotic ingredients in | ||||||
13 | recognized
therapeutic amounts;
| ||||||
14 | (7) not more than 500 milligrams of opium per 100 | ||||||
15 | milliliters or per
100 grams, or not more than 25 | ||||||
16 | milligrams per dosage unit, with one or
more active, | ||||||
17 | non-narcotic ingredients in recognized therapeutic | ||||||
18 | amounts;
| ||||||
19 | (8) not more than 50 milligrams of morphine
per 100 | ||||||
20 | milliliters or per 100 grams with one or more active,
| ||||||
21 | non-narcotic ingredients in recognized therapeutic | ||||||
22 | amounts.
| ||||||
23 | (f) Anabolic steroids, except the following anabolic | ||||||
24 | steroids that are
exempt:
| ||||||
25 | (1) Androgyn L.A.;
| ||||||
26 | (2) Andro-Estro 90-4;
|
| |||||||
| |||||||
1 | (3) depANDROGYN;
| ||||||
2 | (4) DEPO-T.E.;
| ||||||
3 | (5) depTESTROGEN;
| ||||||
4 | (6) Duomone;
| ||||||
5 | (7) DURATESTRIN;
| ||||||
6 | (8) DUO-SPAN II;
| ||||||
7 | (9) Estratest;
| ||||||
8 | (10) Estratest H.S.;
| ||||||
9 | (11) PAN ESTRA TEST;
| ||||||
10 | (12) Premarin with Methyltestosterone;
| ||||||
11 | (13) TEST-ESTRO Cypionates;
| ||||||
12 | (14) Testosterone Cyp 50 Estradiol Cyp 2;
| ||||||
13 | (15) Testosterone Cypionate-Estradiol Cypionate | ||||||
14 | injection; and
| ||||||
15 | (16) Testosterone Enanthate-Estradiol Valerate | ||||||
16 | injection.
| ||||||
17 | (g) Hallucinogenic
substances.
| ||||||
18 | (1) Dronabinol (synthetic) in sesame oil and | ||||||
19 | encapsulated in a soft
gelatin capsule in a U.S.
Food and | ||||||
20 | Drug Administration approved product. Some other names for
| ||||||
21 | dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
| ||||||
22 | 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)
pyran-1-ol) or | ||||||
23 | (-)-delta-9-(trans)-tetrahydrocannabinol.
| ||||||
24 | (2) (Reserved).
| ||||||
25 | (h) The Department may except by rule any compound, | ||||||
26 | mixture, or
preparation containing any stimulant or depressant |
| |||||||
| |||||||
1 | substance listed in
subsection (b) from the application of all | ||||||
2 | or any part of this
Act if the compound, mixture, or | ||||||
3 | preparation contains one or more active
medicinal ingredients | ||||||
4 | not having a stimulant or depressant effect on the
central | ||||||
5 | nervous system, and if the admixtures are included therein in
| ||||||
6 | combinations, quantity, proportion, or concentration that | ||||||
7 | vitiate the
potential for abuse of the substances which have a | ||||||
8 | stimulant or
depressant effect on the central nervous system.
| ||||||
9 | (Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10; | ||||||
10 | 97-334, eff. 1-1-12.)
| ||||||
11 | (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)
| ||||||
12 | Sec. 401. Manufacture or delivery, or possession with | ||||||
13 | intent to
manufacture or deliver, a controlled substance, a | ||||||
14 | counterfeit substance, or controlled substance analog. Except | ||||||
15 | as authorized by this Act, it is unlawful for any
person | ||||||
16 | knowingly to manufacture or deliver, or possess with intent to
| ||||||
17 | manufacture or deliver, a controlled substance other than | ||||||
18 | methamphetamine and other than bath salts as defined in the | ||||||
19 | Bath Salts Prohibition Act sold or offered for sale in a retail | ||||||
20 | mercantile establishment as defined in Section 16-0.1 of the | ||||||
21 | Criminal Code of 2012, a counterfeit substance, or a controlled
| ||||||
22 | substance analog. A violation of this Act with respect to each | ||||||
23 | of the controlled
substances listed herein constitutes a single | ||||||
24 | and separate violation of this
Act. For purposes of this | ||||||
25 | Section, "controlled substance analog" or "analog"
means a |
| |||||||
| |||||||
1 | substance, other than a controlled substance, which is not | ||||||
2 | approved by the United States Food and Drug Administration or, | ||||||
3 | if approved, is not dispensed or possessed in accordance with | ||||||
4 | State or federal law, and that has a chemical structure | ||||||
5 | substantially similar to that of a controlled
substance in | ||||||
6 | Schedule I or II, or that was specifically designed to produce
| ||||||
7 | an effect substantially similar to that of a controlled | ||||||
8 | substance in Schedule
I or II. Examples of chemical classes in | ||||||
9 | which controlled substance analogs
are found include, but are | ||||||
10 | not limited to, the following: phenethylamines,
N-substituted | ||||||
11 | piperidines, morphinans, ecgonines, quinazolinones, | ||||||
12 | substituted
indoles, and arylcycloalkylamines. For purposes of | ||||||
13 | this Act, a controlled
substance analog shall be treated in the | ||||||
14 | same manner as the controlled
substance to which it is | ||||||
15 | substantially similar.
| ||||||
16 | (a) Any person who violates this Section with respect to | ||||||
17 | the following
amounts of controlled or counterfeit substances | ||||||
18 | or controlled substance
analogs, notwithstanding any of the | ||||||
19 | provisions of subsections (c),
(d), (e), (f), (g) or (h) to the | ||||||
20 | contrary, is guilty of a Class X felony
and shall be sentenced | ||||||
21 | to a term of imprisonment as provided in this subsection
(a) | ||||||
22 | and fined as provided in subsection (b):
| ||||||
23 | (1) (A) not less than 6 years and not more than 30 | ||||||
24 | years with respect
to 15 grams or more but less than | ||||||
25 | 100 grams of a substance containing
heroin, or an | ||||||
26 | analog thereof;
|
| |||||||
| |||||||
1 | (B) not less than 9 years and not more than 40 | ||||||
2 | years with respect to 100
grams or more but less than | ||||||
3 | 400 grams of a substance containing heroin, or
an | ||||||
4 | analog thereof;
| ||||||
5 | (C) not less than 12 years and not more than 50 | ||||||
6 | years with respect to
400 grams or more but less than | ||||||
7 | 900 grams of a substance containing heroin,
or an | ||||||
8 | analog thereof;
| ||||||
9 | (D) not less than 15 years and not more than 60 | ||||||
10 | years with respect to
900 grams or more of any | ||||||
11 | substance containing heroin, or an analog thereof;
| ||||||
12 | (1.5) (A) not less than 6 years and not more than 30 | ||||||
13 | years with respect to 15 grams or more but less than | ||||||
14 | 100 grams of a substance containing fentanyl, or an | ||||||
15 | analog thereof; | ||||||
16 | (B) not less than 9 years and not more than 40 | ||||||
17 | years with respect to 100 grams or more but less than | ||||||
18 | 400 grams of a substance containing fentanyl, or an | ||||||
19 | analog thereof; | ||||||
20 | (C) not less than 12 years and not more than 50 | ||||||
21 | years with respect to 400 grams or more but less than | ||||||
22 | 900 grams of a substance containing fentanyl, or an | ||||||
23 | analog thereof; | ||||||
24 | (D) not less than 15 years and not more than 60 | ||||||
25 | years with respect to 900 grams or more of a substance | ||||||
26 | containing fentanyl, or an analog thereof; |
| |||||||
| |||||||
1 | (2) (A) not less than 6 years and not more than 30 | ||||||
2 | years with respect
to 15 grams or more but less than | ||||||
3 | 100 grams of a substance containing
cocaine, or an | ||||||
4 | analog thereof;
| ||||||
5 | (B) not less than 9 years and not more than 40 | ||||||
6 | years with respect to 100
grams or more but less than | ||||||
7 | 400 grams of a substance containing cocaine, or
an | ||||||
8 | analog thereof;
| ||||||
9 | (C) not less than 12 years and not more than 50 | ||||||
10 | years with respect to
400 grams or more but less than | ||||||
11 | 900 grams of a substance containing cocaine,
or an | ||||||
12 | analog thereof;
| ||||||
13 | (D) not less than 15 years and not more than 60 | ||||||
14 | years with respect to
900 grams or more of any | ||||||
15 | substance containing cocaine, or an analog thereof;
| ||||||
16 | (3) (A) not less than 6 years and not more than 30 | ||||||
17 | years with respect
to 15 grams or more but less than | ||||||
18 | 100 grams of a substance containing
morphine, or an | ||||||
19 | analog thereof;
| ||||||
20 | (B) not less than 9 years and not more than 40 | ||||||
21 | years with respect to
100 grams or more but less than | ||||||
22 | 400 grams of a substance containing morphine,
or an | ||||||
23 | analog thereof;
| ||||||
24 | (C) not less than 12 years and not more than 50 | ||||||
25 | years with respect to
400 grams or more but less than | ||||||
26 | 900 grams of a substance containing
morphine, or an |
| |||||||
| |||||||
1 | analog thereof;
| ||||||
2 | (D) not less than 15 years and not more than 60 | ||||||
3 | years with respect to
900 grams or more of a substance | ||||||
4 | containing morphine, or an analog thereof;
| ||||||
5 | (4) 200 grams or more of any substance containing | ||||||
6 | peyote, or an
analog thereof;
| ||||||
7 | (5) 200 grams or more of any substance containing a | ||||||
8 | derivative of
barbituric acid or any of the salts of a | ||||||
9 | derivative of barbituric acid, or
an analog thereof;
| ||||||
10 | (6) 200 grams or more of any substance containing | ||||||
11 | amphetamine
or any salt of an optical isomer of | ||||||
12 | amphetamine,
or an analog thereof;
| ||||||
13 | (6.5) (blank);
| ||||||
14 | (6.6) (blank);
| ||||||
15 | (7) (A) not less than 6 years and not more than 30 | ||||||
16 | years with respect
to: (i) 15 grams or more but less | ||||||
17 | than 100 grams of a substance containing
lysergic acid | ||||||
18 | diethylamide (LSD), or an analog thereof, or (ii) 15 or
| ||||||
19 | more objects or 15 or more segregated parts of an | ||||||
20 | object or objects but
less than 200 objects or 200 | ||||||
21 | segregated parts of an object or objects
containing in | ||||||
22 | them or having upon them any amounts of any substance
| ||||||
23 | containing lysergic acid diethylamide (LSD), or an | ||||||
24 | analog thereof;
| ||||||
25 | (B) not less than 9 years and not more than 40 | ||||||
26 | years with respect
to: (i) 100 grams or more but less |
| |||||||
| |||||||
1 | than 400 grams of a substance containing
lysergic acid | ||||||
2 | diethylamide (LSD), or an analog thereof, or (ii) 200 | ||||||
3 | or more
objects or 200 or more segregated parts of an | ||||||
4 | object or objects but less
than 600 objects or less | ||||||
5 | than 600 segregated parts of an object or objects
| ||||||
6 | containing in them or having upon them any amount of | ||||||
7 | any substance
containing lysergic acid diethylamide | ||||||
8 | (LSD), or an analog thereof;
| ||||||
9 | (C) not less than 12 years and not more than 50 | ||||||
10 | years with respect
to: (i) 400 grams or more but less | ||||||
11 | than 900 grams of a substance containing
lysergic acid | ||||||
12 | diethylamide (LSD), or an analog thereof, or (ii) 600 | ||||||
13 | or more
objects or 600 or more segregated parts of an | ||||||
14 | object or objects but less
than 1500 objects or 1500 | ||||||
15 | segregated parts of an object or objects
containing in | ||||||
16 | them or having upon them any amount of any substance
| ||||||
17 | containing lysergic acid diethylamide (LSD), or an | ||||||
18 | analog thereof;
| ||||||
19 | (D) not less than 15 years and not more than 60 | ||||||
20 | years with respect
to: (i) 900 grams or more of any | ||||||
21 | substance containing lysergic acid
diethylamide (LSD), | ||||||
22 | or an analog thereof, or (ii) 1500 or more objects or
| ||||||
23 | 1500 or more segregated parts of an object or objects | ||||||
24 | containing in them or
having upon them any amount of a | ||||||
25 | substance containing lysergic acid
diethylamide (LSD), | ||||||
26 | or an analog thereof;
|
| |||||||
| |||||||
1 | (7.5) (A) not less than 6 years and not more than 30 | ||||||
2 | years with respect
to:
(i) 15
grams or more but less | ||||||
3 | than 100 grams of a substance listed in paragraph (1),
| ||||||
4 | (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), | ||||||
5 | (21), (25), or (26) of subsection
(d) of Section 204, | ||||||
6 | or an analog or derivative thereof, or (ii) 15 or more
| ||||||
7 | pills, tablets, caplets, capsules, or objects but less | ||||||
8 | than 200 pills, tablets,
caplets, capsules, or objects | ||||||
9 | containing in them or having upon them any
amounts of | ||||||
10 | any substance listed in paragraph (1), (2), (2.1), | ||||||
11 | (2.2), (3), (14.1),
(19), (20), (20.1), (21), (25), or | ||||||
12 | (26) of subsection (d) of Section 204, or
an analog or | ||||||
13 | derivative thereof;
| ||||||
14 | (B) not less than 9 years and not more than 40 | ||||||
15 | years with respect to:
(i) 100 grams or more but less | ||||||
16 | than 400 grams of a substance listed in
paragraph (1), | ||||||
17 | (2), (2.1), (2.2), (3), (14.1), (19), (20),
(20.1), | ||||||
18 | (21), (25), or (26) of subsection (d) of Section 204, | ||||||
19 | or an analog or
derivative thereof, or (ii) 200 or more | ||||||
20 | pills, tablets, caplets, capsules, or
objects but less | ||||||
21 | than 600 pills, tablets, caplets, capsules, or objects
| ||||||
22 | containing in them or having upon them any amount of | ||||||
23 | any substance listed in
paragraph (1), (2), (2.1), | ||||||
24 | (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or | ||||||
25 | (26)
of subsection (d) of Section 204, or an analog or | ||||||
26 | derivative thereof;
|
| |||||||
| |||||||
1 | (C) not less than 12 years and not more than 50 | ||||||
2 | years with respect to:
(i) 400 grams or more but less | ||||||
3 | than 900 grams of a substance listed in
paragraph (1), | ||||||
4 | (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), | ||||||
5 | (21), (25), or (26)
of subsection (d) of Section 204, | ||||||
6 | or an analog or derivative thereof,
or (ii) 600 or more | ||||||
7 | pills, tablets, caplets, capsules, or objects but less | ||||||
8 | than
1,500 pills, tablets, caplets, capsules, or | ||||||
9 | objects
containing in them or having upon them any | ||||||
10 | amount of any substance listed in
paragraph (1), (2), | ||||||
11 | (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21), | ||||||
12 | (25), or (26)
of subsection (d) of Section 204, or an | ||||||
13 | analog or derivative thereof;
| ||||||
14 | (D) not less than 15 years and not more than 60 | ||||||
15 | years with respect to:
(i) 900 grams or more of any | ||||||
16 | substance listed in paragraph (1), (2), (2.1),
(2.2), | ||||||
17 | (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of | ||||||
18 | subsection (d) of
Section 204, or an analog or | ||||||
19 | derivative thereof, or (ii) 1,500 or more pills,
| ||||||
20 | tablets, caplets, capsules, or objects containing in | ||||||
21 | them or having upon them
any amount
of a substance | ||||||
22 | listed in paragraph (1), (2), (2.1), (2.2), (3), | ||||||
23 | (14.1), (19),
(20), (20.1), (21), (25), or (26)
of | ||||||
24 | subsection (d) of Section 204, or an analog or | ||||||
25 | derivative thereof;
| ||||||
26 | (8) 30 grams or more of any substance containing |
| |||||||
| |||||||
1 | pentazocine or any of
the salts, isomers and salts of | ||||||
2 | isomers of pentazocine, or an analog thereof;
| ||||||
3 | (9) 30 grams or more of any substance containing | ||||||
4 | methaqualone or any of
the salts, isomers and salts of | ||||||
5 | isomers of methaqualone, or an analog thereof;
| ||||||
6 | (10) 30 grams or more of any substance containing | ||||||
7 | phencyclidine or any
of the salts, isomers and salts of | ||||||
8 | isomers of phencyclidine (PCP),
or an analog thereof;
| ||||||
9 | (10.5) 30 grams or more of any substance containing | ||||||
10 | ketamine
or any of the salts, isomers and salts of isomers | ||||||
11 | of ketamine,
or an analog thereof;
| ||||||
12 | (10.6) 100 grams or more of any substance containing | ||||||
13 | hydrocodone, or any of the salts, isomers and salts of | ||||||
14 | isomers of hydrocodone, or an analog thereof; | ||||||
15 | (10.7) (blank); 100 grams or more of any substance | ||||||
16 | containing dihydrocodeinone, or any of the salts, isomers | ||||||
17 | and salts of isomers of dihydrocodeinone, or an analog | ||||||
18 | thereof; | ||||||
19 | (10.8) 100 grams or more of any substance containing | ||||||
20 | dihydrocodeine, or any of the salts, isomers and salts of | ||||||
21 | isomers of dihydrocodeine, or an analog thereof; | ||||||
22 | (10.9) 100 grams or more of any substance containing | ||||||
23 | oxycodone, or any of the salts, isomers and salts of | ||||||
24 | isomers of oxycodone, or an analog thereof; | ||||||
25 | (11) 200 grams or more of any substance containing any | ||||||
26 | other controlled
substance classified in Schedules I or II, |
| |||||||
| |||||||
1 | or an analog thereof, which is
not otherwise included in | ||||||
2 | this subsection.
| ||||||
3 | (b) Any person sentenced with respect to violations of | ||||||
4 | paragraph (1),
(2), (3), (7), or (7.5) of subsection (a) | ||||||
5 | involving
100 grams or
more of the
controlled substance named | ||||||
6 | therein, may in addition to the penalties
provided therein, be | ||||||
7 | fined an amount not more than $500,000 or the full
street value | ||||||
8 | of the controlled or counterfeit substance or controlled | ||||||
9 | substance
analog, whichever is greater. The term "street value" | ||||||
10 | shall have the
meaning ascribed in Section 110-5 of the Code of | ||||||
11 | Criminal Procedure of
1963. Any person sentenced with respect | ||||||
12 | to any other provision of
subsection (a), may in addition to | ||||||
13 | the penalties provided therein, be fined
an amount not to | ||||||
14 | exceed $500,000. | ||||||
15 | (b-1) Excluding violations of this Act when the controlled | ||||||
16 | substance is fentanyl, any person sentenced to a term of | ||||||
17 | imprisonment with respect to violations of Section 401, 401.1, | ||||||
18 | 405, 405.1, 405.2, or 407, when the substance containing the | ||||||
19 | controlled substance contains any amount of fentanyl, 3 years | ||||||
20 | shall be added to the term of imprisonment imposed by the | ||||||
21 | court, and the maximum sentence for the offense shall be | ||||||
22 | increased by 3 years.
| ||||||
23 | (c) Any person who violates this Section with regard to the
| ||||||
24 | following amounts of controlled or counterfeit substances
or | ||||||
25 | controlled substance analogs, notwithstanding any of the | ||||||
26 | provisions of
subsections (a), (b), (d), (e), (f), (g) or (h) |
| |||||||
| |||||||
1 | to the
contrary, is guilty of a Class 1 felony. The fine for | ||||||
2 | violation of this
subsection (c) shall not be more than | ||||||
3 | $250,000:
| ||||||
4 | (1) 1 gram or more but less than 15 grams of any
| ||||||
5 | substance containing heroin, or an analog thereof;
| ||||||
6 | (1.5) 1 gram or more but less than 15 grams of any | ||||||
7 | substance containing fentanyl, or an analog thereof; | ||||||
8 | (2) 1 gram or more but less than 15
grams of any | ||||||
9 | substance containing cocaine, or an analog thereof;
| ||||||
10 | (3) 10 grams or more but less than 15 grams of any | ||||||
11 | substance
containing morphine, or an analog thereof;
| ||||||
12 | (4) 50 grams or more but less than 200 grams of any | ||||||
13 | substance
containing peyote, or an analog thereof;
| ||||||
14 | (5) 50 grams or more but less than 200 grams of any | ||||||
15 | substance
containing a derivative of barbituric acid or any | ||||||
16 | of the salts of a
derivative of barbituric acid, or an | ||||||
17 | analog thereof;
| ||||||
18 | (6) 50 grams or more but less than 200 grams of any | ||||||
19 | substance
containing amphetamine or any salt of an optical | ||||||
20 | isomer
of amphetamine, or an analog thereof;
| ||||||
21 | (6.5) (blank);
| ||||||
22 | (7) (i) 5 grams or more but less than 15 grams of any | ||||||
23 | substance
containing lysergic acid diethylamide (LSD), or | ||||||
24 | an analog thereof,
or (ii)
more than 10 objects or more | ||||||
25 | than 10 segregated parts of an object or objects
but less | ||||||
26 | than 15 objects or less than 15 segregated parts of an |
| |||||||
| |||||||
1 | object
containing in them or having upon them any amount of | ||||||
2 | any substance
containing lysergic acid diethylamide (LSD), | ||||||
3 | or an analog thereof;
| ||||||
4 | (7.5) (i) 5 grams or more but less than 15 grams of any | ||||||
5 | substance listed
in paragraph (1), (2), (2.1), (2.2), (3), | ||||||
6 | (14.1), (19), (20), (20.1), (21), (25), or
(26) of | ||||||
7 | subsection (d) of Section 204, or an analog or derivative | ||||||
8 | thereof, or
(ii) more than 10 pills, tablets, caplets, | ||||||
9 | capsules, or objects but less than
15 pills, tablets, | ||||||
10 | caplets, capsules, or objects containing in them or having
| ||||||
11 | upon them any amount of any substance listed in paragraph | ||||||
12 | (1), (2), (2.1),
(2.2), (3), (14.1), (19), (20), (20.1), | ||||||
13 | (21), (25), or (26) of subsection (d) of
Section 204, or an | ||||||
14 | analog or derivative thereof;
| ||||||
15 | (8) 10 grams or more but less than 30 grams of any | ||||||
16 | substance
containing pentazocine or any of the salts, | ||||||
17 | isomers and salts of isomers of
pentazocine, or an analog | ||||||
18 | thereof;
| ||||||
19 | (9) 10 grams or more but less than 30 grams of any | ||||||
20 | substance
containing methaqualone or any of the salts, | ||||||
21 | isomers and salts of isomers
of methaqualone, or an analog | ||||||
22 | thereof;
| ||||||
23 | (10) 10 grams or more but less than 30 grams of any | ||||||
24 | substance
containing phencyclidine or any of the salts, | ||||||
25 | isomers and salts of isomers
of phencyclidine (PCP), or an | ||||||
26 | analog thereof;
|
| |||||||
| |||||||
1 | (10.5) 10 grams or more but less than 30 grams of any | ||||||
2 | substance
containing ketamine or any of the salts, isomers | ||||||
3 | and salts of
isomers of ketamine, or an analog thereof;
| ||||||
4 | (10.6) 50 grams or more but less than 100 grams of any | ||||||
5 | substance containing hydrocodone, or any of the salts, | ||||||
6 | isomers and salts of isomers of hydrocodone, or an analog | ||||||
7 | thereof; | ||||||
8 | (10.7) (blank); 50 grams or more but less than 100 | ||||||
9 | grams of any substance containing dihydrocodeinone, or any | ||||||
10 | of the salts, isomers and salts of isomers of | ||||||
11 | dihydrocodeinone, or an analog thereof; | ||||||
12 | (10.8) 50 grams or more but less than 100 grams of any | ||||||
13 | substance containing dihydrocodeine, or any of the salts, | ||||||
14 | isomers and salts of isomers of dihydrocodeine, or an | ||||||
15 | analog thereof; | ||||||
16 | (10.9) 50 grams or more but less than 100 grams of any | ||||||
17 | substance containing oxycodone, or any of the salts, | ||||||
18 | isomers and salts of isomers of oxycodone, or an analog | ||||||
19 | thereof; | ||||||
20 | (11) 50 grams or more but less than 200 grams of any | ||||||
21 | substance
containing a substance classified in Schedules I | ||||||
22 | or II, or an analog
thereof, which is not otherwise | ||||||
23 | included in this subsection.
| ||||||
24 | (c-5) (Blank).
| ||||||
25 | (d) Any person who violates this Section with regard to any | ||||||
26 | other
amount of a controlled or counterfeit substance |
| |||||||
| |||||||
1 | containing dihydrocodeinone or dihydrocodeine or classified in
| ||||||
2 | Schedules I or II, or an analog thereof, which is (i) a | ||||||
3 | narcotic
drug, (ii) lysergic acid diethylamide (LSD) or an | ||||||
4 | analog thereof,
(iii) any
substance containing amphetamine or | ||||||
5 | fentanyl or any salt or optical
isomer of amphetamine or | ||||||
6 | fentanyl, or an analog thereof, or (iv) any
substance | ||||||
7 | containing N-Benzylpiperazine (BZP) or any salt or optical
| ||||||
8 | isomer of N-Benzylpiperazine (BZP), or an analog thereof, is | ||||||
9 | guilty
of a Class 2 felony. The fine for violation of this | ||||||
10 | subsection (d) shall
not be more than $200,000.
| ||||||
11 | (d-5) (Blank).
| ||||||
12 | (e) Any person who violates this Section with regard to any | ||||||
13 | other
amount of a controlled substance other than | ||||||
14 | methamphetamine or counterfeit substance classified in
| ||||||
15 | Schedule I or II, or an analog thereof, which substance is not
| ||||||
16 | included under subsection (d) of this Section, is
guilty of a | ||||||
17 | Class 3 felony. The fine for violation of this subsection (e)
| ||||||
18 | shall not be more than $150,000.
| ||||||
19 | (f) Any person who violates this Section with regard to any | ||||||
20 | other
amount of a controlled or counterfeit substance | ||||||
21 | classified in
Schedule III is guilty of a Class 3 felony. The | ||||||
22 | fine for violation of
this subsection (f) shall not be more | ||||||
23 | than $125,000.
| ||||||
24 | (g) Any person who violates this Section with regard to any | ||||||
25 | other
amount of a controlled or counterfeit substance | ||||||
26 | classified
in Schedule IV is guilty of a Class 3 felony. The |
| |||||||
| |||||||
1 | fine for violation of
this subsection (g) shall not be more | ||||||
2 | than $100,000.
| ||||||
3 | (h) Any person who violates this Section with regard to any | ||||||
4 | other
amount of a controlled or counterfeit substance | ||||||
5 | classified in
Schedule V is guilty of a Class 3 felony. The | ||||||
6 | fine for violation of this
subsection (h) shall not be more | ||||||
7 | than $75,000.
| ||||||
8 | (i) This Section does not apply to the manufacture, | ||||||
9 | possession or
distribution of a substance in conformance with | ||||||
10 | the provisions of an approved
new drug application or an | ||||||
11 | exemption for investigational use within the
meaning of Section | ||||||
12 | 505 of the Federal Food, Drug and Cosmetic Act.
| ||||||
13 | (j) (Blank).
| ||||||
14 | (Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17 .)
| ||||||
15 | (720 ILCS 570/402) (from Ch. 56 1/2, par. 1402)
| ||||||
16 | Sec. 402. Except as otherwise authorized by this Act, it is | ||||||
17 | unlawful for
any person knowingly to possess a controlled or | ||||||
18 | counterfeit substance or controlled substance analog.
A | ||||||
19 | violation of this Act with respect to each of the controlled | ||||||
20 | substances
listed herein constitutes a single and separate | ||||||
21 | violation of this Act. For purposes of this Section, | ||||||
22 | "controlled substance analog" or "analog"
means a substance, | ||||||
23 | other than a controlled substance, which is not approved by the | ||||||
24 | United States Food and Drug Administration or, if approved, is | ||||||
25 | not dispensed or possessed in accordance with State or federal |
| |||||||
| |||||||
1 | law, and that has a chemical structure substantially similar to | ||||||
2 | that of a controlled
substance in Schedule I or II, or that was | ||||||
3 | specifically designed to produce
an effect substantially | ||||||
4 | similar to that of a controlled substance in Schedule
I or II. | ||||||
5 | Examples of chemical classes in which controlled substance | ||||||
6 | analogs
are found include, but are not limited to, the | ||||||
7 | following: phenethylamines,
N-substituted piperidines, | ||||||
8 | morphinans, ecgonines, quinazolinones, substituted
indoles, | ||||||
9 | and arylcycloalkylamines. For purposes of this Act, a | ||||||
10 | controlled
substance analog shall be treated in the same manner | ||||||
11 | as the controlled
substance to which it is substantially | ||||||
12 | similar.
| ||||||
13 | (a) Any person who violates this Section with respect to | ||||||
14 | the following
controlled or counterfeit substances and | ||||||
15 | amounts, notwithstanding any of the
provisions of subsections | ||||||
16 | (c) and (d) to the
contrary, is guilty of a Class 1 felony and | ||||||
17 | shall, if sentenced to a term
of imprisonment, be sentenced as | ||||||
18 | provided in this subsection (a) and fined
as provided in | ||||||
19 | subsection (b):
| ||||||
20 | (1) (A) not less than 4 years and not more than 15 | ||||||
21 | years with respect
to 15 grams or more but less than | ||||||
22 | 100 grams of a substance containing heroin;
| ||||||
23 | (B) not less than 6 years and not more than 30 | ||||||
24 | years with respect to 100
grams or more but less than | ||||||
25 | 400 grams of a substance containing heroin;
| ||||||
26 | (C) not less than 8 years and not more than 40 |
| |||||||
| |||||||
1 | years with respect to 400
grams or more but less than | ||||||
2 | 900 grams of any substance containing heroin;
| ||||||
3 | (D) not less than 10 years and not more than 50 | ||||||
4 | years with respect to
900 grams or more of any | ||||||
5 | substance containing heroin;
| ||||||
6 | (2) (A) not less than 4 years and not more than 15 | ||||||
7 | years with respect
to 15 grams or more but less than | ||||||
8 | 100 grams of any substance containing
cocaine;
| ||||||
9 | (B) not less than 6 years and not more than 30 | ||||||
10 | years with respect to 100
grams or more but less than | ||||||
11 | 400 grams of any substance containing cocaine;
| ||||||
12 | (C) not less than 8 years and not more than 40 | ||||||
13 | years with respect to 400
grams or more but less than | ||||||
14 | 900 grams of any substance containing cocaine;
| ||||||
15 | (D) not less than 10 years and not more than 50 | ||||||
16 | years with respect to
900 grams or more of any | ||||||
17 | substance containing cocaine;
| ||||||
18 | (3) (A) not less than 4 years and not more than 15 | ||||||
19 | years with respect
to 15 grams or more but less than | ||||||
20 | 100 grams of any substance containing
morphine;
| ||||||
21 | (B) not less than 6 years and not more than 30 | ||||||
22 | years with respect to 100
grams or more but less than | ||||||
23 | 400 grams of any substance containing morphine;
| ||||||
24 | (C) not less than 6 years and not more than 40 | ||||||
25 | years with respect to 400
grams or more but less than | ||||||
26 | 900 grams of any substance containing morphine;
|
| |||||||
| |||||||
1 | (D) not less than 10 years and not more than 50 | ||||||
2 | years with respect to
900 grams or more of any | ||||||
3 | substance containing morphine;
| ||||||
4 | (4) 200 grams or more of any substance containing | ||||||
5 | peyote;
| ||||||
6 | (5) 200 grams or more of any substance containing a | ||||||
7 | derivative of
barbituric acid or any of the salts of a | ||||||
8 | derivative of barbituric acid;
| ||||||
9 | (6) 200 grams or more of any substance containing | ||||||
10 | amphetamine or any salt
of an optical isomer of | ||||||
11 | amphetamine;
| ||||||
12 | (6.5) (blank);
| ||||||
13 | (7) (A) not less than 4 years and not more than 15 | ||||||
14 | years with respect
to: (i) 15 grams or more but less | ||||||
15 | than 100 grams of any substance containing
lysergic | ||||||
16 | acid diethylamide (LSD), or an analog thereof, or (ii) | ||||||
17 | 15 or
more objects or 15 or more segregated parts of an | ||||||
18 | object or objects but
less than 200 objects or 200 | ||||||
19 | segregated parts of an object or objects
containing in | ||||||
20 | them or having upon them any amount of any substance
| ||||||
21 | containing lysergic acid diethylamide (LSD), or an | ||||||
22 | analog thereof;
| ||||||
23 | (B) not less than 6 years and not more than 30 | ||||||
24 | years with respect
to: (i) 100 grams or more but less | ||||||
25 | than 400 grams of any substance
containing lysergic | ||||||
26 | acid diethylamide (LSD), or an analog thereof, or (ii)
|
| |||||||
| |||||||
1 | 200 or more objects or 200 or more segregated parts of | ||||||
2 | an object or objects
but less than 600 objects or less | ||||||
3 | than 600 segregated parts of an object or
objects | ||||||
4 | containing in them or having upon them any amount of | ||||||
5 | any substance
containing lysergic acid diethylamide | ||||||
6 | (LSD), or an analog thereof;
| ||||||
7 | (C) not less than 8 years and not more than 40 | ||||||
8 | years with respect
to: (i) 400 grams or more but less | ||||||
9 | than 900 grams of any substance
containing lysergic | ||||||
10 | acid diethylamide (LSD), or an analog thereof, or (ii)
| ||||||
11 | 600 or more objects or 600 or more segregated parts of | ||||||
12 | an object or objects
but less than 1500 objects or 1500 | ||||||
13 | segregated parts of an object or objects
containing in | ||||||
14 | them or having upon them any amount of any substance
| ||||||
15 | containing lysergic acid diethylamide (LSD), or an | ||||||
16 | analog thereof;
| ||||||
17 | (D) not less than 10 years and not more than 50 | ||||||
18 | years with respect
to: (i) 900 grams or more of any | ||||||
19 | substance containing lysergic acid
diethylamide (LSD), | ||||||
20 | or an analog thereof, or (ii) 1500 or more objects or
| ||||||
21 | 1500 or more segregated parts of an object or objects | ||||||
22 | containing in them or
having upon them any amount of a | ||||||
23 | substance containing lysergic acid
diethylamide (LSD), | ||||||
24 | or an analog thereof;
| ||||||
25 | (7.5) (A) not less than 4 years and not more than 15 | ||||||
26 | years with respect
to: (i) 15
grams or more but
less |
| |||||||
| |||||||
1 | than 100 grams of any substance listed in paragraph | ||||||
2 | (1), (2), (2.1), (2.2), (3),
(14.1), (19),
(20), | ||||||
3 | (20.1), (21), (25), or (26) of subsection (d) of | ||||||
4 | Section 204, or an
analog or derivative
thereof, or | ||||||
5 | (ii) 15 or more pills, tablets, caplets, capsules, or | ||||||
6 | objects but
less than 200 pills,
tablets, caplets, | ||||||
7 | capsules, or objects containing in them or having upon | ||||||
8 | them
any amount of any
substance listed in paragraph | ||||||
9 | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), | ||||||
10 | (20.1),
(21), (25), or (26) of
subsection (d) of | ||||||
11 | Section 204, or an analog or derivative thereof;
| ||||||
12 | (B) not less than 6 years and not more than 30 | ||||||
13 | years with respect to: (i)
100
grams or more but
less | ||||||
14 | than 400 grams of any substance listed in paragraph | ||||||
15 | (1), (2), (2.1), (2.2), (3),
(14.1), (19), (20),
| ||||||
16 | (20.1), (21), (25), or (26) of subsection (d) of | ||||||
17 | Section 204, or an analog or
derivative thereof, or
| ||||||
18 | (ii) 200 or more pills, tablets, caplets, capsules, or | ||||||
19 | objects but less than
600
pills, tablets,
caplets, | ||||||
20 | capsules, or objects containing in them or having upon | ||||||
21 | them any amount
of any
substance
listed in paragraph | ||||||
22 | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), | ||||||
23 | (20.1), (21),
(25), or (26) of subsection
(d) of | ||||||
24 | Section 204, or an analog or derivative thereof;
| ||||||
25 | (C) not less than 8 years and not more than 40 | ||||||
26 | years with respect to: (i)
400
grams or more but
less |
| |||||||
| |||||||
1 | than 900 grams of any substance listed in paragraph | ||||||
2 | (1), (2), (2.1), (2.2), (3),
(14.1), (19), (20),
| ||||||
3 | (20.1), (21), (25), or (26) of subsection (d) of | ||||||
4 | Section 204, or an analog or
derivative thereof,
or | ||||||
5 | (ii) 600 or more pills, tablets, caplets, capsules, or | ||||||
6 | objects but less than
1,500 pills, tablets,
caplets, | ||||||
7 | capsules, or objects containing in them or having upon | ||||||
8 | them any amount
of any
substance listed in paragraph | ||||||
9 | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), | ||||||
10 | (20.1),
(21), (25), or (26) of
subsection (d) of | ||||||
11 | Section 204, or an analog or derivative thereof;
| ||||||
12 | (D) not less than 10 years and not more than 50 | ||||||
13 | years with respect to:
(i)
900 grams or more of
any | ||||||
14 | substance listed in paragraph (1), (2), (2.1), (2.2), | ||||||
15 | (3), (14.1), (19), (20),
(20.1), (21), (25), or (26)
of | ||||||
16 | subsection (d) of Section 204, or an analog or | ||||||
17 | derivative thereof, or (ii)
1,500 or more pills,
| ||||||
18 | tablets, caplets, capsules, or objects containing in | ||||||
19 | them or having upon them
any amount of a
substance | ||||||
20 | listed in paragraph (1), (2), (2.1), (2.2), (3), | ||||||
21 | (14.1), (19), (20), (20.1),
(21), (25), or (26) of
| ||||||
22 | subsection (d) of Section 204, or an analog or | ||||||
23 | derivative thereof;
| ||||||
24 | (8) 30 grams or more of any substance containing | ||||||
25 | pentazocine or any of
the salts, isomers and salts of | ||||||
26 | isomers of pentazocine, or an analog thereof;
|
| |||||||
| |||||||
1 | (9) 30 grams or more of any substance containing | ||||||
2 | methaqualone or any
of the salts, isomers and salts of | ||||||
3 | isomers of methaqualone;
| ||||||
4 | (10) 30 grams or more of any substance containing | ||||||
5 | phencyclidine or any
of the salts, isomers and salts of | ||||||
6 | isomers of phencyclidine (PCP);
| ||||||
7 | (10.5) 30 grams or more of any substance containing | ||||||
8 | ketamine or any of
the salts, isomers and salts of isomers | ||||||
9 | of ketamine;
| ||||||
10 | (11) 200 grams or more of any substance containing any | ||||||
11 | substance
classified as a narcotic drug in Schedules I or | ||||||
12 | II, or an analog thereof, which is not otherwise
included | ||||||
13 | in this subsection.
| ||||||
14 | (b) Any person sentenced with respect to violations of | ||||||
15 | paragraph (1),
(2), (3), (7), or (7.5) of subsection (a) | ||||||
16 | involving 100
grams or more of the
controlled substance named | ||||||
17 | therein, may in addition to the penalties
provided therein, be | ||||||
18 | fined an amount not to exceed $200,000 or the full
street value | ||||||
19 | of the controlled or counterfeit substances, whichever is
| ||||||
20 | greater. The term "street value" shall have the meaning
| ||||||
21 | ascribed in Section 110-5 of the Code of Criminal Procedure of | ||||||
22 | 1963. Any
person sentenced with respect to any other provision | ||||||
23 | of subsection (a), may
in addition to the penalties provided | ||||||
24 | therein, be fined an amount not to
exceed $200,000.
| ||||||
25 | (c) Any person who violates this Section with regard to an | ||||||
26 | amount
of a controlled substance other than methamphetamine or |
| |||||||
| |||||||
1 | counterfeit substance not set forth in
subsection (a) or (d) is | ||||||
2 | guilty of a Class 4 felony. The fine for a
violation punishable | ||||||
3 | under this subsection (c) shall not be more
than $25,000.
| ||||||
4 | (d) Any person who violates this Section with regard to any | ||||||
5 | amount of
anabolic steroid is guilty of a Class C misdemeanor
| ||||||
6 | for the first offense and a Class B misdemeanor for a | ||||||
7 | subsequent offense
committed within 2 years of a prior | ||||||
8 | conviction.
| ||||||
9 | (Source: P.A. 99-371, eff. 1-1-16 .)
|